Long-term, the use of BRAF V600E inhibitors can lead to squamous cell carcinoma and keratoacanthoma, which may be attributed to paradoxical activation of MAP kinase in cells lacking the BRAF mutation (83). The gene discussed is BRAF; the disease is squamous cell carcinoma.